Culturally Adapted Materials to Increase Cervical Cancer Screening Among Polish Women in Iceland
Testing of Culturally Adapted Materials to Enhance Participation in Cervical Cancer Screening Among Polish Women Residing in Iceland
This study tests whether sending Polish women residing in Iceland a culturally adapted invitation letter - tailored in language and messaging to the target group - increases participation in cervical cancer screening compared with a standard, non-adapted invitation letter. Eligible women will be randomly assigned to receive one of the two letter types, and screening participation will be tracked over the following months.
調査の概要
状態
詳細な説明
It has been shown that cervical cancer screening participation remains lower among women with immigrant background, compared to the general population. Translating existing screening materials into the languages of the immigrant groups may not be sufficient to motivate screening participation. However, cultural adaptation of cancer screening materials has been suggested as a potential strategy to facilitate screening attendance.
This study investigates whether a culturally adapted invitation letter increases attendance at cervical cancer screening among Polish women residing in Iceland, compared with the standard invitation letter currently used in the national cervical cancer screening program. The adapted letter was developed in collaboration with a focus group from the target population.
All individuals registered as female in Registers Iceland and aged 23-64 years are eligible for cervical cancer screening in accordance with the national cancer screening guidelines issued by the Directorate of Health. Eligible individuals receive an invitation letter both digitally via the national health portal and by post. All eligible individuals receive digital invitations in Icelandic, English and Polish. Paper invitations are available only in Icelandic. Therefore, the culturally adapted letter will only be sent digitally.
Polish-born women residing in Iceland who are due for routine cervical cancer screening will be randomized 1:1 to receive either the culturally adapted invitation letter or the standard invitation letter.
This trial is intended to generate evidence on whether low-cost intervention, such as the cultural adaptation of existing screening materials, may help reduce disparities in screening uptake.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Ásgerður Marteinsdóttir
- 電話番号:+3545136700
- メール:asgerdur.marteinsdottir@heilsugaeslan.is
研究連絡先のバックアップ
- 名前:Ágúst Ingi Ágústsson
- 電話番号:+3545136700
- メール:agust.ingi.agustsson@heilsugaeslan.is
研究場所
-
-
-
Garðabaer、アイスランド、210
- Cancer Screening Coordination Center, Primary Health Care of the Capital Area
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Individuals within the target population for the national cervical cancer screening program in Iceland, defined as those registered as female in the population register and aged 23-64 years
- Born in Poland
- Being due to be invited for cervical cancer screening during the study enrolment period, in accordance with the cervical cancer screening guidelines issued by the Directorate of Health.
Exclusion Criteria:
-Individuals who are not eligible for the national cervical cancer screening program in Iceland (non-female, outside the screening age and not due for an invitation (time since last screening attendance)).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Culturally adapted invitation letter
Participants in this arm receive a screening invitation letter which has been culturally adapted, developed with community input. |
Participants randomized to the intervention group will receive a screening invitation letter which has been culturally adapted, developed with community input from individuals in the target group. The letter provides information about cervical cancer screening and has been adapted to the language, cultural context, and communication needs of the target population of Polish women residing in Iceland. The adapted letter retains the essential information contained in the standard invitation while modifying its wording and presentation to improve relevance, understanding, and engagement, with the aim of increasing attendance at cervical cancer screening. The letter will be sent once digitally via the electronic health platforms heilsuvera.is and island.is. |
|
アクティブコンパレータ:Standard cervical cancer screening invitation letter
Participants in this arm receive a standard invitation letter to cervical cancer screening. |
Participants randomized to the control group will receive the standard invitation letter routinely used to invite eligible individuals to cervical cancer screening. The standard letter provides information about the screening programme and instructions for attending screening. The letter will be sent once digitally via the electronic health platforms heilsuvera.is and island.is. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Participation rate in the national cervical cancer screening program in Iceland
時間枠:From the date the invitation is sent through 6 months post-invitation.
|
The primary outcome of this study will be the participation rate in the Icelandic national cervical cancer screening program within 6 months of invitation, defined as a registered cervical sample in the Icelandic Cancer Screening Register. Participation will be coded as a binary variable (yes/no). |
From the date the invitation is sent through 6 months post-invitation.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Participation rate in the national cervical cancer screening program in Iceland
時間枠:From the date the invitation is sent through 3 months post-invitation.
|
The secondary outcome will be the participation rate in the Icelandic national cervical cancer screening program within 3 months of invitation, defined as a registered cervical sample in the Icelandic Cancer Screening Register. Participation will be coded as a binary variable (yes/no). |
From the date the invitation is sent through 3 months post-invitation.
|
協力者と研究者
捜査官
- 主任研究者:Ágúst Ingi Ágústsson, Cand. Med.、Cancer Screening Coordination Center, Primary Health Care of the Capital Area
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- PHCI-2026-001
- 101162959 (その他の助成金/資金番号:EU4Health)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。